High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,

ABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibr...

Full description

Bibliographic Details
Main Authors: Lucia Bencke Geyer, Sergio Saldanha Menna Barreto, Liese Loureiro Weigert, Adriane Ribeiro Teixeira
Format: Article
Language:English
Published: Elsevier 2015-12-01
Series:Brazilian Journal of Otorhinolaryngology
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=en
id doaj-2cbc0a19a4a34e8589c4d43b425bc54e
record_format Article
spelling doaj-2cbc0a19a4a34e8589c4d43b425bc54e2021-03-02T09:48:34ZengElsevierBrazilian Journal of Otorhinolaryngology1808-86862015-12-0181658959710.1016/j.bjorl.2015.08.011S1808-86942015000600589High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,Lucia Bencke GeyerSergio Saldanha Menna BarretoLiese Loureiro WeigertAdriane Ribeiro TeixeiraABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibrosis by High Frequency Audiometry and Distortion Product Otoacoustic Emissions. METHODS: Cross-sectional study. The study group consisted of 39 patients (7-20 years of age) with cystic fibrosis and a control group of 36 individuals in the same age group without otologic complaints, with normal audiometric thresholds and type A tympanometric curves. High Frequency Audiometry and Distortion Product Otoacoustic Emissions tests were conducted. RESULTS: The study group had significantly higher thresholds at 250, 1000, 8000, 9000, 10,000, 12,500, and 16,000 Hz (p = 0.004) as well as higher prevalence of otoacoustic emission alterations at 1000 and 6000 Hz (p = 0.001), with significantly lower amplitudes at 1000, 1400, and 6000 Hz. There was a significant association between alterations in hearing thresholds in High Frequency Audiometry with the number of courses of aminoglycosides administered (p = 0.005). Eighty-three percent of patients who completed more than ten courses of aminoglycosides had hearing loss in High Frequency Audiometry. CONCLUSION: A significant number of patients with cystic fibrosis who received repeated courses of aminoglycosides showed alterations in High Frequency Audiometry and Distortion Product Otoacoustic Emissions. The implementation of ten or more aminoglycoside cycles was associated with alterations in High Frequency Audiometry.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=enFibrose císticaAminoglicosídeosAudiometria
collection DOAJ
language English
format Article
sources DOAJ
author Lucia Bencke Geyer
Sergio Saldanha Menna Barreto
Liese Loureiro Weigert
Adriane Ribeiro Teixeira
spellingShingle Lucia Bencke Geyer
Sergio Saldanha Menna Barreto
Liese Loureiro Weigert
Adriane Ribeiro Teixeira
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
Brazilian Journal of Otorhinolaryngology
Fibrose cística
Aminoglicosídeos
Audiometria
author_facet Lucia Bencke Geyer
Sergio Saldanha Menna Barreto
Liese Loureiro Weigert
Adriane Ribeiro Teixeira
author_sort Lucia Bencke Geyer
title High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
title_short High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
title_full High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
title_fullStr High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
title_full_unstemmed High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
title_sort high frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
publisher Elsevier
series Brazilian Journal of Otorhinolaryngology
issn 1808-8686
publishDate 2015-12-01
description ABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibrosis by High Frequency Audiometry and Distortion Product Otoacoustic Emissions. METHODS: Cross-sectional study. The study group consisted of 39 patients (7-20 years of age) with cystic fibrosis and a control group of 36 individuals in the same age group without otologic complaints, with normal audiometric thresholds and type A tympanometric curves. High Frequency Audiometry and Distortion Product Otoacoustic Emissions tests were conducted. RESULTS: The study group had significantly higher thresholds at 250, 1000, 8000, 9000, 10,000, 12,500, and 16,000 Hz (p = 0.004) as well as higher prevalence of otoacoustic emission alterations at 1000 and 6000 Hz (p = 0.001), with significantly lower amplitudes at 1000, 1400, and 6000 Hz. There was a significant association between alterations in hearing thresholds in High Frequency Audiometry with the number of courses of aminoglycosides administered (p = 0.005). Eighty-three percent of patients who completed more than ten courses of aminoglycosides had hearing loss in High Frequency Audiometry. CONCLUSION: A significant number of patients with cystic fibrosis who received repeated courses of aminoglycosides showed alterations in High Frequency Audiometry and Distortion Product Otoacoustic Emissions. The implementation of ten or more aminoglycoside cycles was associated with alterations in High Frequency Audiometry.
topic Fibrose cística
Aminoglicosídeos
Audiometria
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=en
work_keys_str_mv AT luciabenckegeyer highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients
AT sergiosaldanhamennabarreto highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients
AT lieseloureiroweigert highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients
AT adrianeribeiroteixeira highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients
_version_ 1724238435217047552